Financial Performance - Company reported net sales of $118 million for Q4 2025, a 27% increase from $93 million in Q4 2024 [4] - Full year 2025 net sales reached $419 million, reflecting a 20% growth compared to $349 million in 2024 [5] - Fourth quarter GAAP net income was $15 million, with earnings per share of $0.10, compared to $7 million and $0.05 in Q4 2024 [12][38] - Adjusted EBITDA for Q4 2025 was $29 million, representing 25% of net sales [2][4] Product Performance - Wound product sales grew by 28% in Q4 2025, driven by the introduction of EPIXPRESS® and contributions from EMERGE™ [4] - Surgical sales increased by 25% in Q4 2025, marking the sixth consecutive quarter of growth, led by AMNIOFIX® and AMNIOEFFECT® [4][5] Gross Profit and Margin - Gross profit for Q4 2025 was $99 million, up from $76 million in Q4 2024, with a gross margin of 84% [8][9] - For the full year 2025, gross profit was $346 million, maintaining a gross margin of 83% [9] Operating Expenses - SG&A expenses for Q4 2025 were $73 million, an increase from $61 million in Q4 2024, primarily due to higher commissions [10] - R&D expenses for Q4 2025 were $5 million, compared to $4 million in Q4 2024, driven by ongoing product development [11] Cash Position - As of December 31, 2025, the company had $166 million in cash and cash equivalents, up from $104 million a year earlier [13] - The cash position, net of debt, was $148 million, reflecting a $63 million increase for the year [13] Share Repurchase Program - Company announced a $100 million share repurchase program, providing flexibility to buy back shares over a two-year period [14][15] Financial Outlook - For 2026, the company estimates net sales between $340 million and $360 million, with an adjusted EBITDA margin in the mid-to-high teens [16]

Core Insights - MiMedx Group, Inc. has launched EPIXPRESS®, a new lyophilized human placental allograft aimed at enhancing its Advanced Wound Care (AWC) product portfolio [1][2] Product Overview - EPIXPRESS is designed to treat acute and chronic hard-to-heal wounds, featuring a tri-layer configuration and fenestrations for improved fluid movement [2][3] - The product is suitable for various conditions, including diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), and is effective for deep or tunneling wounds [2][3] Company Background - MiMedx is a leader in the wound care sector, focusing on innovative solutions for chronic and hard-to-heal wounds, with a vision to be the global provider of healing solutions [4]